Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis
Junjie Peng,Min Wang,Yanqiu Wu,Yongchun Shen,Lei Chen
DOI: https://doi.org/10.2147/COPD.S374079
2022-10-12
International Journal of COPD
Abstract:Junjie Peng, &ast Min Wang, &ast Yanqiu Wu, &ast Yongchun Shen, Lei Chen Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lei Chen; Yongchun Shen, Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, People's Republic of China, Email ; Background: Some clinical indicators have been reported to be useful in differentiating asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) from pure asthma/COPD, but the results were inconsistent. This study aims to evaluate the diagnostic value of these indicators for ACO. Methods: Databases of PubMed, EMBASE, Ovid and Web of Science were retrieved. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated in random-effects models. Results: 48 eligible studies were included. The pooled results indicated, compared with pure asthma, ACO patients had lower levels of forced expiratory volume in the first second (FEV 1 )% predicted (pred) (SMD=− 1.09, 95% CI − 1.3 to − 0.87), diffusion lung capacity for carbon monoxide (DLCO)% pred (SMD=− 0.83, 95% CI − 1.24 to − 0.42), fractional exhaled nitric oxide (FeNO) (SMD=− 0.23, 95% CI − 0.36 to − 0.11), and higher levels of induced sputum neutrophil (SMD = 0.51, 95% CI 0.21 to 0.81), circulating YKL-40 (SMD = 0.96, 95% CI 0.27 to 1.64). However, relative to COPD alone, ACO patients had higher levels of FEV 1 % pred (SMD = 0.15, 95% CI 0.05 to 0.26), DLCO% pred (SMD = 0.38, 95% CI 0.16 to 0.6), FeNO (SMD = 0.59, 95% CI 0.40 to 0.78), serum total immunoglobulin (Ig)E (SMD = 0.42, 95% CI 0.1 to 0.75), blood eosinophil (SMD = 0.44, 95% CI 0.29 to 0.59), induced sputum eosinophil (SMD = 0.62, 95% CI 0.42 to 0.83), and lower levels of induced sputum neutrophil (SMD=− 0.48, 95% CI − 0.7 to − 0.27), circulating YKL-40 (SMD=− 1.09, 95% CI − 1.92 to − 0.26). Conclusion: Compared with pure asthma/COPD, ACO patients have different levels of FEV 1 % pred, DLCO% pred, FeNO, serum total IgE, blood eosinophil, induced sputum eosinophil/neutrophil, and circulating YKL-40, which could be helpful to establish a clinical diagnosis of ACO. Keywords: asthma, asthma-COPD overlap, COPD, indicators, meta-analysis Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a term to describe patients with both features of asthma and COPD, firstly proposed by a joint section of the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) in 2014, and revised to "ACO" in GINA 2017. 1 ACO is epidemiologically considered in 2% of the general population, 29.6% of asthmatic patients and 26.5% of COPD patients. 2 Patients with ACO have a greater burden of symptoms, frequent exacerbations, poor quality of life, a more rapid decline in lung function and greater use of healthcare resources compared to patients with asthma or COPD alone, but global diagnostic criteria for ACO are inconclusive. 3,4 To date, asthma and COPD are considered as two different types of chronic airway inflammation. 5,6 T-helper (Th) 2 inflammatory pattern plays an important role in the development and progression of asthma, which is indicated by blood/sputum eosinophil, serum total immunoglobulin (Ig) E, circulating periostin and fractional exhaled nitric oxide (FeNO). 1,5 However, COPD is often characterized by Th1 inflammation, dominated by macrophages and neutrophils. 6 ACO shares some inflammatory characteristics between asthma and COPD, and in the past few years, some clinical indicators were reported to be useful in differentiating ACO from pure asthma or COPD, but the results were inconsistent. 7–10 Therefore, we performed a systematic review and meta-analysis to evaluate the potential diagnostic value of these clinical indicators, including post-bronchodilator forced expiratory volume in the first second (FEV 1 )% predicted (pred), diffusing capacity of the lungs for carbon monoxide (DLCO)% pred, FeNO, serum total IgE, blood/induced sputum eosinophil, induced sputum neutrophil, and circulating YKL-40/periostin/neutrophil gelatinase-associated lipocalin (NGAL). This meta-analysis was reported in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) ( Table S1 ). 11 We systematically retrieved databases of PubMed, EMBASE, Ovid and Web of Science from inception to March 2022, with restrictions of human study and English lang -Abstract Truncated-